3 reports of this reaction
1.5% of all COCOA BUTTER, PHENYLEPHRINE HCL reports
#14 most reported adverse reaction
NASOPHARYNGITIS is the #14 most commonly reported adverse reaction for COCOA BUTTER, PHENYLEPHRINE HCL, manufactured by Amerisourcebergen Drug Corporation. There are 3 FDA adverse event reports linking COCOA BUTTER, PHENYLEPHRINE HCL to NASOPHARYNGITIS. This represents approximately 1.5% of all 199 adverse event reports for this drug.
Patients taking COCOA BUTTER, PHENYLEPHRINE HCL who experience nasopharyngitis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NASOPHARYNGITIS is a less commonly reported adverse event for COCOA BUTTER, PHENYLEPHRINE HCL, but still significant enough to appear in the safety profile.
In addition to nasopharyngitis, the following adverse reactions have been reported for COCOA BUTTER, PHENYLEPHRINE HCL:
The following drugs have also been linked to nasopharyngitis in FDA adverse event reports:
NASOPHARYNGITIS has been reported as an adverse event in 3 FDA reports for COCOA BUTTER, PHENYLEPHRINE HCL. This does not prove causation, but indicates an association observed in post-market surveillance data.
NASOPHARYNGITIS accounts for approximately 1.5% of all adverse event reports for COCOA BUTTER, PHENYLEPHRINE HCL, making it a notable side effect.
If you experience nasopharyngitis while taking COCOA BUTTER, PHENYLEPHRINE HCL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.